![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
September 17, 2024
A recent amendment expands eligibility for this phase 2 trial evaluating the use of green tea catechin pills to help prevent progression
September 17, 2024
Summaries of recently published ECOG-ACRIN research results
August 14, 2024
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
July 3, 2024
Summaries of recently published ECOG-ACRIN research results
June 11, 2024
Summaries of five ECOG-ACRIN trials presented at the 2024 American Society of Clinical Oncology Annual Meeting
April 9, 2024
Summaries of recently published ECOG-ACRIN research results
March 7, 2024
Summaries of recently published ECOG-ACRIN research results
February 9, 2024
Amidst a persistent drug shortage, the BRIDGE trial seeks another possible first-line treatment option for patients
October 19, 2023
This randomized phase 3 trial explores repeated focused radiation to control disease and spare patients with renal cell carcinoma from systemic therapy for months or even years
August 25, 2023
The changes broaden eligibility for prostate cancer patients and make baseline scanning easier for sites in this phase 3 trial using PET imaging to guide treatment for recurrence
August 25, 2023
Summaries of recently published ECOG-ACRIN research results
June 30, 2023
This phase 3 study aims to determine the optimal sequencing of surgery, chemotherapy, and chemoradiotherapy for patients with cancer of the penis